Gen1E Lifesciences

Rare Diseases

Also Clin1 undisclosed; GEn-1123 Clin0 kidney condition; GEn-1912 Clin0 oncology

Gen1E Lifesciences is a clinical-stage, phase 2 company focused on developing innovative immunomodulatory therapies for rare and inflammatory diseases with limited treatment options. Their AI-powered drug development platform, GRID AI, enables them to rapidly identify and optimize novel drug candidates. Gen1E’s GRID AI platform spans from discovery to clinical studies enabling efficient drug development. Their platform uses neural networks and disease mapping databases to identify other indications for each new drug they discover and accelerate the drug development process. Gen1E is exploring therapies for various inflammatory conditions, including autoimmune diseases and respiratory disorders. Gen1E Lifesciences’ lead product, GEn-1124, is a small molecule, a non-catalytic p38α/MK2 dual signal modulator, being developed for the treatment of acute respiratory distress syndrome (ARDS).

Jobs:

News: